Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer

Phase II Study to Evaluate Efficacy and Safety of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer. This Study is an Extension Study for Japanese Registration Only.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00344552

Enrollment

Registered

2006-06-27

Start date

2006-06-30

Completion date

2008-03-31

Last updated

2009-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer

Brief summary

The purpose of this clinical research study is to learn if BMS-181339 can shrink or slow the growth of the cancer in patients with advanced or recurrent esophageal cancer. The safety of this treatment will also be studied.

Interventions

DRUGPaclitaxel

Injection solution, IV, 100mg/sqm, once weekly, 7 weeks and over

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients must have measurable disease * Patients must have experienced on pervious chemotherapy regime * Men and Women, with the age 20 years or older * ECOG PS: 0-1

Exclusion criteria

* Patients with previous therapy with Taxanes

Design outcomes

Primary

Measure	Time frame
Overall response rate	at the end of the study
Safety	at the end of the study

Secondary

Measure	Time frame
Response duration	at the end of the study
Time to progression (TTP)	at the end of the study

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026